| Cases |
Hubs | Hubbers | Topics | Request |
| #1 in Business | Subscribe Email Print |
|
You are here: Home > Business > Business > Should We Admit Failure? |
|
Cases - Should We Admit Failure?
Failure is something that none of us ever plans for but it is a part of the human condition. As we go through our lives there are According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product few if any who have never experienced this phenomenon. So as we experience failure, how do we accept it and move on if we are un ; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug. Examples of combination products may in able to admit it? I am not suggesting that when we fail that we broadcast our failure to the world at large. I am suggesting tho lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together. gh that admitting failure is a necessary tool that we must use if we are ever to be successful again. An admission of failure is here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe a very personal thing and it should be done with those whom we have a special relationship. Often we can find it difficult to ad d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations. Combination pro mit to those we love that we have failed. It is especially difficult to admit failure to those who had expected it from the begin ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc ing. To be wildly successful at anything requires us to go into a venture with a narrow definition of what success looks like. i easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi f we have not defined success before we attempt something, how do we know when it is time to give up on it and try something else nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically ? Most people define success as having a dollar amount attached to it, but it is always not a financial reward that comes with s and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ ccess, often success is totally unrelated to finance. Therefore as we work in a business we must be prepared to make a determina ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi tion as to what success in that business looks like. If our success depends on a financial reward, we need to know what we must d ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it. Following aspects would a o to achieve that reward, otherwise we are at risk of failure. If on the other hand success is determined by the impact that we h dd to the challenges in developing combination products: Which markets to tap where the combination products can do fairly well? Which combination prod ve on the lives of others, we can not always expect that this success will have financial reward. So is it possible then to actu cts are meaningful and rational? Which therapeutic categories to select? Which Combinations can address unmet needs of the patients? Do combin ally fail and succeed at the same time? This is the point that I would like you to ponder. As you go through your life, ask yours tions increase the patient compliance? What would be the developing cost? How to tackle the risks encountered during combination product developmen elf what the impact is that you have had on the lives of others. Then weigh that impact on the result that you have achieved. It t? As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel ay not be a situation where you can claim a financial victory immediately, but it may also be a situation where you are primed to ping new procedures for reviewing their safety, efficacy and quality. Professional from academic institutions, pharmaceutical industries, health care indust go forward and accomplish something that will reap a great financial reward. It is with this thought that I would like to close y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products this article. I know you have read the books that used this phrase and I believe that to achieve success we must all be prepared . As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de to live by these words. Whether we are successful now or have been in the past, we are all involved in a process of "Failing Forw elopment. They need to be wiser in analyzing the market trends and the regulatory requirements. Companies that provide selfless information through particip ard" and it is in this common condition that we should all remember to be supportive of others when we see their need for support tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
Related Articles:The Effectiveness of Corporate Communication The 'S' Corporation is a Dinosaur How To Incorporate In California
|